183 related articles for article (PubMed ID: 38166947)
1. NCAPG2 promotes prostate cancer malignancy and stemness via STAT3/c-MYC signaling.
Zhang E; Chen Z; Liu W; Lin L; Wu L; Guan J; Wang J; Kong C; Bi J; Zhang M
J Transl Med; 2024 Jan; 22(1):12. PubMed ID: 38166947
[TBL] [Abstract][Full Text] [Related]
2. NCAPG2 overexpression promotes hepatocellular carcinoma proliferation and metastasis through activating the STAT3 and NF-κB/miR-188-3p pathways.
Meng F; Zhang S; Song R; Liu Y; Wang J; Liang Y; Wang J; Han J; Song X; Lu Z; Yang G; Pan S; Li X; Liu Y; Zhou F; Wang Y; Cui Y; Zhang B; Ma K; Zhang C; Sun Y; Xin M; Liu L
EBioMedicine; 2019 Jun; 44():237-249. PubMed ID: 31176678
[TBL] [Abstract][Full Text] [Related]
3. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2.
Zhao D; Pan C; Sun J; Gilbert C; Drews-Elger K; Azzam DJ; Picon-Ruiz M; Kim M; Ullmer W; El-Ashry D; Creighton CJ; Slingerland JM
Oncogene; 2015 Jun; 34(24):3107-19. PubMed ID: 25151964
[TBL] [Abstract][Full Text] [Related]
4. CUL4B/miR-33b/C-MYC axis promotes prostate cancer progression.
Zhao M; Qi M; Li X; Hu J; Zhang J; Jiao M; Bai X; Peng X; Han B
Prostate; 2019 Apr; 79(5):480-488. PubMed ID: 30609075
[TBL] [Abstract][Full Text] [Related]
5. GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy.
Mukha A; Kahya U; Linge A; Chen O; Löck S; Lukiyanchuk V; Richter S; Alves TC; Peitzsch M; Telychko V; Skvortsov S; Negro G; Aschenbrenner B; Skvortsova II; Mirtschink P; Lohaus F; Hölscher T; Neubauer H; Rivandi M; Labitzky V; Lange T; Franken A; Behrens B; Stoecklein NH; Toma M; Sommer U; Zschaeck S; Rehm M; Eisenhofer G; Schwager C; Abdollahi A; Groeben C; Kunz-Schughart LA; Baretton GB; Baumann M; Krause M; Peitzsch C; Dubrovska A
Theranostics; 2021; 11(16):7844-7868. PubMed ID: 34335968
[TBL] [Abstract][Full Text] [Related]
6. NCAPG2 contributes to the progression of malignant melanoma through regulating proliferation and metastasis.
Feng Z; Zhang L; Liu Y; Zhang W
Biochem Cell Biol; 2022 Dec; 100(6):473-484. PubMed ID: 36265182
[TBL] [Abstract][Full Text] [Related]
7. Transcription factor FoxM1 is the downstream target of c-Myc and contributes to the development of prostate cancer.
Pan H; Zhu Y; Wei W; Shao S; Rui X
World J Surg Oncol; 2018 Mar; 16(1):59. PubMed ID: 29554906
[TBL] [Abstract][Full Text] [Related]
8. A regulatory circuit HP1γ/miR-451a/c-Myc promotes prostate cancer progression.
Chang C; Liu J; He W; Qu M; Huang X; Deng Y; Shen L; Zhao X; Guo H; Jiang J; Fu XY; Huang R; Zhang D; Yan J
Oncogene; 2018 Jan; 37(4):415-426. PubMed ID: 28967902
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-27a-5p regulation by promoter methylation and MYC signaling in prostate carcinogenesis.
Barros-Silva D; Costa-Pinheiro P; Duarte H; Sousa EJ; Evangelista AF; Graça I; Carneiro I; Martins AT; Oliveira J; Carvalho AL; Marques MM; Henrique R; Jerónimo C
Cell Death Dis; 2018 Feb; 9(2):167. PubMed ID: 29415999
[TBL] [Abstract][Full Text] [Related]
10. NCAPG2 facilitates glioblastoma cells' malignancy and xenograft tumor growth via HBO1 activation by phosphorylation.
Wu J; Li L; Jiang G; Zhan H; Zhu X; Yang W
Cell Tissue Res; 2021 Feb; 383(2):693-706. PubMed ID: 32897418
[TBL] [Abstract][Full Text] [Related]
11. PSCA promotes prostate cancer proliferation and cell-cycle progression by up-regulating c-Myc.
Li E; Liu L; Li F; Luo L; Zhao S; Wang J; Kang R; Luo J; Zhao Z
Prostate; 2017 Dec; 77(16):1563-1572. PubMed ID: 28971496
[TBL] [Abstract][Full Text] [Related]
12. MYC and NCAPG2 as molecular targets of colorectal cancer and gastric cancer in nursing.
Mi X; Shan H; Kang C; Zhang J; Hou S; Gao Y; Hao L; Gao X; Gao Q; Chi X; Zhang Q
Medicine (Baltimore); 2024 May; 103(18):e38029. PubMed ID: 38701261
[TBL] [Abstract][Full Text] [Related]
13. SOX4 is activated by C-MYC in prostate cancer.
Dong H; Hu J; Wang L; Qi M; Lu N; Tan X; Yang M; Bai X; Zhan X; Han B
Med Oncol; 2019 Sep; 36(11):92. PubMed ID: 31560094
[TBL] [Abstract][Full Text] [Related]
14. Metformin targets c-MYC oncogene to prevent prostate cancer.
Akinyeke T; Matsumura S; Wang X; Wu Y; Schalfer ED; Saxena A; Yan W; Logan SK; Li X
Carcinogenesis; 2013 Dec; 34(12):2823-32. PubMed ID: 24130167
[TBL] [Abstract][Full Text] [Related]
15. PLEK2 promotes cancer stemness and tumorigenesis of head and neck squamous cell carcinoma via the c-Myc-mediated positive feedback loop.
Zhao X; Shu D; Sun W; Si S; Ran W; Guo B; Cui L
Cancer Commun (Lond); 2022 Oct; 42(10):987-1007. PubMed ID: 36002342
[TBL] [Abstract][Full Text] [Related]
16. SREBP-2 promotes stem cell-like properties and metastasis by transcriptional activation of c-Myc in prostate cancer.
Li X; Wu JB; Li Q; Shigemura K; Chung LW; Huang WC
Oncotarget; 2016 Mar; 7(11):12869-84. PubMed ID: 26883200
[TBL] [Abstract][Full Text] [Related]
17. ACYP2 contributes to malignant progression of glioma through promoting Ca
Li M; Ruan B; Wei J; Yang Q; Chen M; Ji M; Hou P
J Exp Clin Cancer Res; 2020 Jun; 39(1):106. PubMed ID: 32517717
[TBL] [Abstract][Full Text] [Related]
18. Targeting SMYD2 inhibits prostate cancer cell growth by regulating c-Myc signaling.
Li J; Wan F; Zhang J; Zheng S; Yang Y; Hong Z; Dai B
Mol Carcinog; 2023 Jul; 62(7):940-950. PubMed ID: 37036190
[TBL] [Abstract][Full Text] [Related]
19. MAZ promotes prostate cancer bone metastasis through transcriptionally activating the KRas-dependent RalGEFs pathway.
Yang Q; Lang C; Wu Z; Dai Y; He S; Guo W; Huang S; Du H; Ren D; Peng X
J Exp Clin Cancer Res; 2019 Sep; 38(1):391. PubMed ID: 31488180
[TBL] [Abstract][Full Text] [Related]
20. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
